BPMC / Blueprint Medicines Corporation - Insider Trading and Ownership Report - SEC Form 3, 4, 5

Insider Trading Chart

Insider Roster and Profitability Metrics

This table shows the list known insiders, and is generated automatically from filings disclosed to the SEC. In addition to the names, most recent title, and director, officer, or 10% owner designation, we provide the latest disclosed holdings. Additionally, when possible we provide the historical trade performance for the insider. The historical trade performance is a weighted average of the performance of actual open-market purchase transactions made by the insider. For more information on how this is calculated, watch this YouTube webinar.

See our leaderboard of most profitable insider traders.

Report errors via our new Insider Auditing Tool

Track Records of Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BPMC / Blueprint Medicines Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical .

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2022-11-03	Haviland Kate	1,100	43.9800	1,100	43.9800	48,378	238	66.37	24,629	50.91
2022-03-03	Goldberg Mark Alan	5,000	59.9800	5,000	59.9800	299,900
2021-07-13	Demetri George	10	82.6600	10	82.6600	827
2015-05-05	FMR LLC / Fidelity Management & Research	125,000	18.0000	125,000	18.0000	2,250,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Track Records of Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BPMC / Blueprint Medicines Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical .

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
2025-07-03	Carter Percy H.	1,051	128.2500	1,051	128.2500	134,791	0	128.3500	106	0.08
2025-07-03	Rossi Christina	1,172	128.2500	1,172	128.2500	150,309
2025-06-03	Carter Percy H.	241	127.8800	241	127.8800	30,819
2025-06-03	Carter Percy H.	2,418	127.8800	2,418	127.8800	309,214
2025-03-05	Durso-Bumpus Debra	5,157	88.8000	5,157	88.8000	457,942
2025-03-05	Carter Percy H.	3,530	88.8000	3,530	88.8000	313,464
2025-03-05	Hurley Ariel	1,326	88.8000	1,326	88.8000	117,749
2025-03-05	Haviland Kate	16,151	88.8000	16,151	88.8000	1,434,209
2025-03-05	Landsittel Michael	5,284	88.8000	5,284	88.8000	469,219

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.